[CAS NO. 229961-45-9] AGN194310
PRODUCTS SPECIFICATIONS [229961-45-9]
DESCRIPTION [229961-45-9]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 424.55 |
| Molecular Formula | C28H24O2S |
| SMILES | CC(S1)(C)C=C(C2=CC=C(CC)C=C2)C3=C1C=CC(C#CC4=CC=C(C(O)=O)C=C4)=C3 |
4 Publications Citing Use of MCE
Summary
In Vitro
AGN194310 potently inhibits colony formation by all three lines, with IC50 values of 16 nM for LNCaP cells; 18 nM for PC3 cells; and 34 nM for DU-145 cells
[2]
.
AGN 194310 (50 nM, 100 nM; LNCaP, PC-3 and DU-145 cells) inhibits colony formation at concentrations of 50 nM and 100 nM alone and in combination with TTNPB
[2]
.
AGN 194310 (1 μM; 72 hours; LNCaP cells) treatment results in 80% apoptosis
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [2]
| Cell Line: | LNCaP, PC-3 and DU-145 cells. |
| Concentration: | 50 nM, 100 nM |
| Incubation Time: | |
| Result: | When used together with 100 nM TTNPB, there was almost complete reversal of the growth inhibitory effect of 50 nM and partial reversal of the effect of 100 nM. |
Apoptosis Analysis [2]
| Cell Line: | LNCaP cells |
| Concentration: | 1 μM |
| Incubation Time: | 72 hours |
| Result: | Induced apoptosis in LNCaP cells. |
In Vivo
AGN 194310 (0.5 mg/kg/day; oral gavage; every day; for 10 days; female C57Bl/6J mice) treatment increases the number of granulocytes across haemopoietic compartments. A significant increase in the frequency of granulocyte-progenitor cells is observed in the bone marrow of mice after treatment with AGN194310 [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Female C57Bl/6J mice (Five-week-old (34-37 days)) [3] |
| Dosage: | 0.5 mg/kg/day |
| Administration: | Oral gavage; every day; for 10 days |
| Result: | The number of granulocytes was significantly increased across haemopoietic compartments. Progenitor cells containing granulocytes also increased significantly. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 50 mg/mL ( 117.77 mM ; ultrasonic and warming and heat to 60°C)
H 2 O : < 0.1 mg/mL (insoluble)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.3554 mL | 11.7772 mL | 23.5544 mL |
| 5 mM | 0.4711 mL | 2.3554 mL | 4.7109 mL |
| 10 mM | 0.2355 mL | 1.1777 mL | 2.3554 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 1 mg/mL (2.36 mM); Clear solution
References
- [1] Johnson AT, et al. Synthesis and biological activity of high-affinity retinoic acid receptor antagonists. Bioorg Med Chem. 1999 Jul;7(7):1321-38.
- [2] Hammond LA, et al. Antagonists of retinoic acid receptors (RARs) are potent growth inhibitors of prostate carcinoma cells. Br J Cancer. 2001 Aug 3;85(3):453-62.
- [3] Walkley CR, et al. Retinoic acid receptor antagonism in vivo expands the numbers of precursor cells during granulopoiesis. Leukemia. 2002 Sep;16(9):1763-72.